Inhibikase reports Q3 2026 results, updates IMPROVE-PAH Phase 3 progress for IKT-001Nov 10Quarterly updateIKT-001Inhibikase Therapeutics
Inhibikase names Kailera CMO Scott Wasserman to board, Berman resignsOct 20PeopleIKT-001Inhibikase Therapeutics
Inhibikase reports Q2 2026 results as Phase 3 PAH trial expands across 26 countriesAug 11Quarterly updateInhibikase Therapeutics
FDA grants orphan drug status to Inhibikase's IKT-001 for PAHJul 23Regulatory milestoneIKT-001Inhibikase Therapeutics